Published in Cancer Res on February 01, 2000
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
The role of HER2 in cancer therapy and targeted drug delivery. J Control Release (2010) 1.88
Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene (2007) 1.69
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene (2010) 1.17
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16
External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci U S A (2002) 0.94
Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2. Clin Exp Med (2015) 0.82
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation. Breast Cancer Res (2014) 0.80
Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs. ACS Nano (2015) 0.78
Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. Biomed Res Int (2015) 0.77
Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. Eur J Nucl Med Mol Imaging (2003) 0.76
Comparing the Effect of Silybin and Silybin Advanced™ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation. Iran J Pharm Res (2015) 0.76
Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma. Oncol Lett (2016) 0.75
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature (1985) 6.23
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 2.75
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg (2001) 2.40
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature (1985) 1.88
Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med (1995) 1.81
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A (1986) 1.56
Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A (1987) 1.52
Evolution and current status of the Whipple procedure: an update for gastroenterologists. Gastroenterology (1997) 1.32
The "hidden cystic duct" syndrome and the infundibular technique of laparoscopic cholecystectomy--the danger of the false infundibulum. J Am Coll Surg (2000) 1.19
Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol (1999) 1.18
Immunocytochemical and neurochemical evidence for age-related loss of GABA in the inferior colliculus: implications for neural presbycusis. J Neurosci (1990) 1.17
Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int (1997) 1.14
Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int (1997) 1.11
Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol (1999) 1.10
Results of a new strategy for reconstruction of biliary injuries having an isolated right-sided component. J Gastrointest Surg (2001) 1.09
A new model of renal microvascular endothelial injury. Kidney Int (1997) 1.06
Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int (1996) 1.05
Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int (1996) 1.04
Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am J Pathol (1994) 1.02
Identification of an I-J+ antigen-presenting cell required for third order suppressor cell activation. J Exp Med (1983) 1.00
Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res (2001) 1.00
Patent ductus arteriosus in the elderly. Chest (1988) 0.99
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene (2008) 0.99
CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol (1998) 0.97
Suppressor T cells and the immune response to tumors. Crit Rev Immunol (1984) 0.96
Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int (1996) 0.95
Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res (2001) 0.94
SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Am J Pathol (1996) 0.93
Genetically restricted antigen presentation for immunological tolerance and suppression. Nature (1984) 0.91
Modulation of experimental mesangial proliferative nephritis by interferon-gamma. Kidney Int (1995) 0.88
Attenuation of immune-mediated glomerulonephritis with an anti-CD11b monoclonal antibody. Am J Physiol (1993) 0.87
Purification of mouse monoclonal antibodies from ascitic fluid by DEAE Affi-Gel Blue chromatography. Methods Enzymol (1986) 0.86
Identification of a cDNA for a human high-molecular-weight B-cell growth factor. Proc Natl Acad Sci U S A (1993) 0.86
Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int (1997) 0.85
Role of leukocytes in metabolic and functional derangements of experimental glomerulonephritis. Am J Physiol (1991) 0.85
Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res (1998) 0.85
Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen. J Immunol (1983) 0.85
Management of diagnostic dilemmas of the pancreas by ultrasonographically guided laparoscopic biopsy. Surgery (1999) 0.84
Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int (1996) 0.84
Regulation of the immune response to antigens on the malignant cell surface. Springer Semin Immunopathol (1982) 0.83
HER2/neu antisense targeting of human breast carcinoma. Oncogene (2000) 0.83
Inhibition of tumor growth by monoclonal anti-I-J antibodies. J Immunol (1983) 0.81
Platelets and neutrophils are critical to the enhanced glomerular arachidonate metabolism in acute nephrotoxic nephritis in rats. J Clin Invest (1993) 0.81
Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int (1996) 0.81
Paradoxical exacerbation of leukocyte-mediated glomerulonephritis with cyclooxygenase inhibition. Am J Physiol (1992) 0.81
Regulation of the immune response to tumor antigens. X. Activation of third-order suppressor T cells that abrogate anti-tumor immune responses. J Immunol (1984) 0.80
Urinary eicosanoids and the assessment of glomerular inflammation. J Am Soc Nephrol (1992) 0.79
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol (2005) 0.79
Analysis of hapten-specific T suppressor factors: genetic restriction of TsF1 activity analyzed with synthetic hybrid suppressor molecules. J Immunol (1984) 0.77
Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. J Am Coll Surg (2000) 0.77
Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery (1999) 0.76
Intravenous immunoglobulin protects against experimental thrombotic microangiopathy. Kidney Int (2001) 0.76
Identification of a cDNA for a human high molecular-weight B-cell growth factor. Proc Natl Acad Sci U S A (1996) 0.75
Pancreaticoduodenectomy for lymphoepithelial cyst of the pancreas. Am Surg (2000) 0.75
Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu. Methods Enzymol (1991) 0.75
Differential antigen presentation in tumor immunity. Fed Proc (1984) 0.75
Development of monoclonal antibodies reactive with the product of the neu oncogene. Symp Fundam Cancer Res (1986) 0.75
The role of antigen-presenting cells in regulating the immune response to tumor antigens. Transplant Proc (1984) 0.75
Role of the 5-lipooxygenase pathway in obstructive nephropathy. Kidney Int (1992) 0.75